Related Experiment Video
Updated: Jul 6, 2026
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
MEK-inhibitors decrease Nfix in muscular dystrophy but induce unexpected calcifications, partially rescued with
Giuseppe Angelini1, Emanuele Capra1, Francesca Rossi1
1Department of Biosciences, University of Milan, 20133 Milan, Italy.
Abstract:
Muscular dystrophies (MDs) are incurable genetic myopathies characterized by progressive degeneration of skeletal muscles. Dystrophic mice lacking the transcription factor Nfix display morphological and functional improvements of the disease. Recently, we demonstrated that MAPK signaling pathway positively regulates Nfix in muscle development and that Cyanidin, a natural antioxidant molecule, strongly ameliorates the pathology. To explore a synergistic approach aimed at treating MDs, we administered Trametinib, a clinically approved MEK inhibitor, alone or combined with Cyanidin to adult Sgca null mice. We observed that chronic treatment with Trametinib and Cyanidin reduced Nfix in myogenic cells but, unexpectedly, caused ectopic calcifications exclusively in dystrophic muscles. The combined treatment with Cyanidin resulted in histological improvements by preventing Trametinib-induced calcifications in Diaphragm and Soleus. Collectively, this first pilot study revealed that Nfix is modulated by the MAPK pathway in MDs, and that Cyanidin partly rescued the unexpected ectopic calcifications caused by MEK inhibition.
Insights
This study investigated Trametinib and Cyanidin for muscular dystrophy (MD). Cyanidin mitigated unexpected calcifications caused by Trametinib, offering a potential synergistic therapeutic approach for MD.
Area of Science:
- Muscle biology
- Genetic disorders
- Pharmacology
Background:
- Muscular dystrophies (MDs) are incurable genetic myopathies causing progressive skeletal muscle degeneration.
- Mice lacking the Nfix transcription factor show improved disease phenotypes.
- The MAPK signaling pathway regulates Nfix, and the antioxidant Cyanidin ameliorates MD pathology.
Purpose of the Study:
- To explore a synergistic therapeutic approach for MDs using Trametinib (MEK inhibitor) and Cyanidin.
- To investigate the effects of combined treatment on Nfix modulation and disease pathology in Sgca null mice.
Main Methods:
- Adult Sgca null mice were treated with Trametinib alone or in combination with Cyanidin.
- Nfix levels in myogenic cells were assessed.
- Histological analysis was performed to evaluate ectopic calcifications and muscle improvements.
Main Results:
- Chronic Trametinib and Cyanidin treatment reduced Nfix in myogenic cells.
- Unexpected ectopic calcifications occurred exclusively in dystrophic muscles.
- Combined Cyanidin treatment prevented Trametinib-induced calcifications in diaphragm and soleus muscles, showing histological improvements.
Conclusions:
- Nfix is modulated by the MAPK pathway in muscular dystrophies.
- Cyanidin partially rescued ectopic calcifications induced by MEK inhibition.
- This study provides a foundation for synergistic therapeutic strategies in MDs.
